Increasing prevalence of chronic diseases and targeted diseases are driving the demand for gene therapy. During viral vector transmission, it is ensured that the viral particle is not infectious. Today, retrovirus adenovirus, adeno-associated virus, and lentivirus are most commonly used as a viral vector globally. These viral vectors market are incorporated with a therapeutic gene to treat different diseases such as cancer and cardiovascular disease. Renova Therapeutics has completed the phase I/II clinical trial of AC6 gene transfer for congestive heart failure disease. According to the American Stroke Association, over 836,540 deaths in the U.S. were reported due to cardiovascular disease.
Gene therapy is majorly preferred for treating Adenosine deaminase (ADA) deficiency . Globally, approximately 1 in 1,000,000 babies born with ADA deficiency, Genetics Home Reference.
Global viral vector manufacturing market is segmented by type, disease, application, end-user, and regions.
Based on type, the viral vector manufacturing market is segmented into Retrovirus Vectors, Adenovirus Vectors, Adeno-Associated Viral Vectors, and others. The adeno-associated viral vector is estimated with the highest market value following its high application for genetic diseases like Fragile X syndrome and retinal defects.
By disease, the viral vector manufacturing market is segmented into cancer, genetic disorders, and infectious disease. Cancer segment is expected to dominate the market during the forecast period. According to the American Cancer Society, around 174,650 new cases and 31,620 deaths due to prostate cancer were reported in 2017. Separate from this, the U.S FDA granted approval to sipuleucel-T (Provenge) of Dendron Corporation for the treatment of prostate cancer.
By application, the viral vector manufacturing market is divided into gene therapy and vaccinology. Gene therapy segment is holding the major market share.
On the basis of end-user, the viral vector manufacturing market is segmented into pharmaceutical and biopharmaceutical companies and research centers. Pharmaceutical and biopharmaceutical companies segment is expected to lead the market during the forecast period.
Geographically, the global viral vector manufacturing market is segmented into North America, Europe, Asia Pacific, and Latin America and the Middle East & Africa (LAMEA).
Got questions about your regional growth of
Viral Vector Manufacturing Market?
Just drop us a line or call on +1 646 480 7505
North America is expected to lead the global viral vector manufacturing market during the forecast period following the rising application of gene therapy for treating various diseases.
Europe is expected to witness considerable growth and is likely to stand second in the global vector manufacturing market. This can be attributed to increasing ongoing treatment for the hematological disorder and cell anemia. The U.K. and France are housing the highest population suffering from genetic diseases in the region. According to Genetic Alliance UK, over 6% of the population is suffering from rare diseases. In March 2019, the European Medicine Agency granted approval to Zynteglo for the treatment of transfusion-dependent beta (β)-thalassemia (TDT).
Asia Pacific market is growing at the highest CAGR following increasing development in drug designing in countries like China, Japan, and India. Moreover, drug development includes chemical drug entity and gene delivering entity. According to the Indian Council of Medical Research, over 2 million people are suffering from cancer, and more than 1.1 million new patients are registered every year.
LAMEA is projected to witness sluggish growth in the global viral vector manufacturing market as a result of low research and development activities and the adoption of gene therapy.
Some of the key players in the global viral vector manufacturing market Merck kGA (Germany), Lonza (Switzerland), BD (U.S.), Fujifilm Diosynth biotechnologies USA Inc (U.S.), Brammer Bio (U.S.), Cell Therapy Catapult Limited (U.K.), Waisman Biomanufacturing (U.S.), GENEZEN LABORATORIES (U.S.), Yposkesi, Inc. (France), and REGENXBIO Inc (U.S)
Today, several market players are increasingly focusing on research & devolvement activities for developing innovative technology in gene therapy and the drug approval process. Some leading players are also trying to expand their geographical presence through acquisition and collaboration with some small-scale industries.
In 2015, the U.S. FDA approved ‘Imlygic’(talimogene laherparepvec), a genetically modified herpes virus used for the treatment of melanoma. In the same year, the European Medical Agency also approved the drug.
In December 2019, the U.S. FDA approved ‘Luxturna’ (voretigene neparvovec-rzyl) of Spark Therapeutics Inc for the treatment of genetic retinal defects.
Viral Vector Manufacturing market Segmentation
By End User
o North America
o South America
o Western Europe
o Eastern Europe
o South Korea
o Rest of Asia Pacific
The Middle East & Africa
o The Middle East
" Crucial Insights The Report Provides:"
* Known and Unknown Adjacencies Influencing the Growth of Market
* Explorable Revenue Sources
* Customer Behaviour Analysis
* Target Partners
* Customized Geographical Data Based on Customers as well as Competitors
* Analysis of Market Size and CAGR between the Forecast PeriodsView Full Report Buy This Report Now